Oramed Pharmaceuticals Inc. (ORMP) Stock Analysis & Investment Frameworks
Oramed Pharmaceuticals Inc. (ORMP) stock analysis on Invetso. Review Oramed Pharmaceuticals Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Oramed Pharmaceuticals Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Oramed Pharmaceuticals Inc. Key Financial Metrics
- Market Cap: $161.81M
- Revenue: $2.00M
- P/E Ratio: 2.53
- ROE: 72.96%
- ROIC: -3.21%
- Dividend Yield: 6.43%
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc., founded in 2002 and based in New York, New York, specializes in the development of groundbreaking pharmaceutical treatments. Their primary focus is on creating orally ingested capsules or pills for the delivery of polypeptides, particularly aimed at managing diabetes. The company's leading product, ORMD-0801, is an oral insulin capsule that has successfully completed Phase II clinical trials for patients with diabetes. Oramed is also advancing ORMD-0901, an oral glucagon-like peptide-1 (GLP-1) capsule, which has concluded Phase I clinical trials for the treatment of type 2 diabetes. Additionally, an oral leptin capsule for weight loss is currently under development. The firm was originally incorporated as Integrated Security Technologies, Inc., before officially changing its name to Oramed Pharmaceuticals Inc. in April 2006.